Literatur
-
1
Arndt P, Volk C, Gorboulev V. et al .
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
Am J Physiol Renal Physiol.
2001;
281
110-115
-
2
Cascorbi I, Gerloff T, Johne A. et al .
Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians.
Clin Pharmacol Ther.
2001;
69
169-174
-
3
Cordon-Cardo C, O’Brien J P, Boccia J, Casals D, Bertino J R, Melamed M R.
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem.
1990;
38
1277-1287
-
4
Dresser M J, Leabman M K, Giacomini K M.
Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters.
J Pharm Sci.
2001;
90
397-421
-
5
Fei Y J, Liu W, Prasad P D. et al .
Identification of the histidyl residue obligatory for the catalytic activity of the human H+/peptide cotransporters PEPT1 and PEPT2.
Biochemistry.
1997;
36
452-460
-
6
Fellay J, Marzolini C, Meaden E R. et al .
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Lancet.
2002;
359
30-36
-
7
Ganapathy M E, Brandsch M, Prasad P D, Ganapathy V, Leibach F H.
Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2.
J Biol Chem.
1995;
270
25 672-25 677
-
8
Gao M, Yamazaki M, Loe D W. et al .
Multidrug resistance protein. Identification of regions required for active transport of leukotriene C4.
J Biol Chem.
1998;
273
10 733-10 740
-
9
Gerloff T, Schaefer M, Johne A. et al .
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.
Br J Clin Pharmacol.
2002;
54
610-616
-
10
Goettler M, Schneeweiss S, Hasford J.
Adverse drug reaction monitoring - cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission.
Pharmacoepidemiol Drug Safety.
1997;
6
S79-90
(Suppl 3)
-
11
Gorboulev V, Ulzheimer J C, Akhoundova A. et al .
Cloning and characterization of two human polyspecific organic cation transporters.
DNA Cell Biol.
1997;
16
871-881
-
12
Greiner B, Eichelbaum M, Fritz P. et al .
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
J Clin Invest.
1999;
104
147-153
-
13
Gründemann D. et al .
Drug excretion mediated by a new prototype of polyspecific transporter.
Nature.
1994;
372
549-552
-
14
Han H, de Vrueh R L, Rhie J K. et al .
5’-Amino acid esters of antiviral nucleosides, iacyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.
Pharm Res.
1998;
15
1154-1159
-
15
Hipfner D R, Mao Q, Qiu W. et al .
Monoclonal antibodies that inhibit the transport function of the 190-kDa multridrug resistance protein, MRP.
J Biol Chem.
1999;
274
15 420-15 426
-
16
Hoffmeyer S, Burk O, von Richter O. et al .
Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.
Proc Natl Acad Sci USA.
2000;
97
3473-3478
-
17
Hu M, Zheng L, Chen J. et al .
Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin.
Pharm Res.
1995;
12
1120-1125
-
18
Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K.
Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.
Pharmacogenetics.
2001;
11
175-184
-
19
Itoda M, Saito Y, Soyama A. et al .
Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5’-untranslated region and exon 28.
Drug Metab Dispos.
2002;
30
363-364
-
20
Johne A, Kopke K, Gerloff T. et al .
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
Clin Pharmacol Ther.
2002;
72
584-594
-
21
Juranka P F, Zastawny R L, Ling V.
P-glykoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins.
FASEB J.
1989;
3
2583-2592
-
22
Kerb R, Brinkmann U, Chatskaia N. et al .
Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences.
Pharmacogenetics.
2002;
12
591-595
-
23
Kim R B, Leake B F, Choo E F. et al .
Identification of functionally variant MDR1 alleles among European Americans and African Americans.
Clin Pharmacol Ther.
2001;
70
189-199
-
24
Koepsell H.
Organic cation transporters in intestine, kidney, liver, and brain.
Annu Rev Physiol.
1998;
60
243-266
-
25
Lazarou J, Bruce H, Pomeranz H, Corey P N.
Incidence of adverse drug reactions in hospitalised patients.
JAMA.
1998;
279
1200-1205
-
26
Mizutani T.
PM frequencies of major CYPs in Asian and Caucasians.
Drug Metab Rev.
2003;
35
99-106
-
27
Nishizato Y, Suzuki H, Kimura M. et al .
Polymorphisms of OATP-C (SCL21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
Clin Pharmacol Ther.
2003;
73
554-565
-
28
Nozawa T, Nakajima M, Tamai I. et al .
Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allelic frequencies in the Japanese population and functional analysis.
J Pharmacol Exp Ther.
2002;
302
804-813
-
29
Paulusma C C, Oude Elferink R P.
The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man.
J Mol Med.
1997;
75
420-428
-
30
Rao V V, Dahlheimer J L, Bardgett M E. et al .
Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.
Proc Natl Acad Sci USA.
1999;
96
3900-3905
-
31 Roots I, Brockmoller J. Pharmakogenetik. 3rd ed Darmstadt: Steinkopff In: Rietbrock N, Staib AH, Loew D, editors. Klinische Pharmakologie 1996: 101-120
-
32
Saito H, Motohashi H, Mukai M, Inui K.
Cloning and characterization of a pH-sensing regulatory factor that modulates transport activity of the human H+/paptide cotransporter, PEPT1.
Biochem Biophys Res Commun.
1997;
237
557-582
-
33
Sakaeda T, Nakamura T, Horinouchi M. et al .
MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.
Pharm Res.
2001;
18
1400-1404
-
34
Siddiqui A, Kerb R, Weale M E. et al .
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.
N Engl J Med.
2003;
348
1442-1448
-
35
Siegmund W, Ludwig K, Giessmann T. et al .
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
Clin Pharmacol Ther.
2002;
72
572-583
-
36
Steijns L S, Van Der Weide J.
Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication.
Clin Chem.
1998;
44
914-917
-
37
Su S F, Huang J D.
Inhibition of the intestinal digoxin absorption and exsorption by quinidine.
Drug Metab Dispos.
1996;
24
142-147
-
38
Tanigawara Y.
Role of P-glykoprotein in drug disposition.
Ther Drug Monit.
2000;
22
137-140
-
39
Temple C S, Boyd C A.
Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter.
Biochim Biophys Acta.
1998;
1373
277-281
-
40
Terada T, Saito H, Mukai M, Inui K I.
Identification of the histidine residues involved in substrate recognition by a rat H+/peptide cotransporter, PEPT1.
FEBS Lett.
1996;
394
196-200
-
41
Tirona R G, Leake B F, Merino G, Kim R B.
Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
J Biol Chem.
2001;
276
35 669-35 675
-
42
Urtti A, Johns S J, Sadee W.
Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pH sensing regulatory splice variant.
AAPS Pharmsci.
2001;
3
1
-
43
Westphal K, Weinbrenner A, Giessmann T. et al .
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Clin Pharmacol Ther.
2000;
68
6-12
Dr. med. Thomas Gerloff
Institut für Klinische Pharmakologie, Charité, Humboldt Universität Berlin
Schumannstraße 20/21
10098 Berlin
Telefon: 030/450525004
Fax: 030/450525933
eMail: thomas.gerloff@charite.de
